San Diego-based Fate Therapeutics, which develops stem cell technology, said today in a regulatory filing that it is looking to sell 4,000,000 shares of its common stock at between $14.00 and $16.00 per share. The firm said it hopes to trade on the NASDAQ Global Market as FATE. Fate Therapeutics is venture backed by ARCH Venture Partners, Polaris Partners, Venrock, and OVP Venture Partners.
Top NewsTuesday, September 3, 2013
Fate Therapeutics Sets IPO Range